

IN THE CLAIMS:

Please cancel Claims 1-27.

Please add the following new claims:

-- Claim 28. A monoclonal antibody that binds to mouse CD40L encoded by vector pDC406-mCD40-L having ATCC Accession No. 68872.

Claim 29. A pharmaceutical composition comprising a monoclonal antibody according to Claim 28, and a pharmaceutically acceptable carrier.

Claim 30. A hybridoma which secretes a monoclonal antibody that binds to mouse CD40L encoded by vector pDC406-mCD40-L having ATCC Accession No. 68872. --

REMARKS

The title has been amended consistent with the claims of the present application.

The specification has been amended for purposes of clarification and to correct obvious typographical errors therein. Support for the amendment regarding pages 37-38 can be found, *inter alia*, in SEQ ID NOs: 15 and 20. The amendments to the specification are essentially identical to those made in parent application Serial No. 08/249,189 (now allowed).

An ATCC deposit receipt for the hybridomas described in the specification is attached hereto.

New Claims 28-30 have been added to more clearly recite the invention of interest. Support for new Claims 28-30 can be found in, *inter alia*, the cancelled Claims, and Examples 4 and 7 provided in the present specification.